LAG3 and T-cell non-Hodgkin lymphoma: In this study, we tested the effects of the novel human immunomodulatory mAbs targeting PD-L1, CTLA-4, and LAG-3 on TNBC and T-cell lymphoma derived cells in comparison with the clinically validated atezolizumab and ipilimumab, by using them as single agents or in combinations, in order to test eventual synergistic or additive effects.